Kamada ( Kamada )

Kamada

Kamada's picture

Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique protein purification technology.

Kamada´s product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide. The Company's pharmaceuticals are produced in its state-of-the-art, cGMP-compliant, FDA-approved, large scale production facility.

Kamada’s flagship product is Glassia®; an FDA approved intravenous (IV) Alpha-1 Antitrypsin (AAT) protein, for the treatment of AAT Deficiency. Glassia® is a high purity, ready to use and stabilizer free augmentation treatment .Kamada has a strategic agreement with Baxter for US marketing, distribution and licensing of Glassia®.

Kamada press release, blog etc

07/10/2018 - 15:50 Kamada Receives Positive Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT
06/04/2018 - 10:01 Results of Kamadas Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Associations 78th Scientific Sessions
04/23/2018 - 22:48 Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
01/08/2018 - 13:54 Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
01/04/2018 - 06:34 Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease
11/22/2017 - 05:58 Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency
11/21/2017 - 05:26 Kamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection
11/10/2017 - 10:12 Amended Notice of 2017 Annual General Meeting of Shareholders
11/01/2017 - 13:49 Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients
09/18/2017 - 05:07 Kamada Announces CFO Transition Gil Efron, Deputy CEO and CFO, to Depart Kamada at End of Year; Chaime Orlev to Assume CFO Duties
09/06/2017 - 00:03 Kamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of Action
09/05/2017 - 23:26 Kamada to Present Corporate Overview at Two Investor Conferences in September
08/25/2017 - 12:38 Kedrion Biopharma and Kamada Receive FDA Approval of KEDRAB for Post-Exposure Prophylaxis Against Rabies Infection
07/28/2017 - 02:43 Kamada Announces Proposed Public Offering of Ordinary Shares
07/28/2017 - 02:04 Kamada Announces Pricing of Public Offering of Ordinary Shares
07/20/2017 - 08:32 Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
06/27/2017 - 10:55 Kamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
06/12/2017 - 05:10 Kamada Receives Additional Milestone Payment Under GLASSIA Exclusive Supply and Distribution Agreement with Shire